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IT is well established that human
solid tumours and oncogenic cell. lines
can be grown in vivo by s.c. implantation
in thymectomized, irradiated mice (T-
B+) (Franks, Perkins and Holmes, 1973,
1975a; Franks et al., 1975b; Cobb and
Mitchley, 1974; Stanbridge et at., 1975;
Franks et al., 1976a), and in congenitally
athymic mice (nunu) (Povlsen and Ry-
gaard, 1971; Rygaard and Povlsen, 1969;
Povlsen and Jacobsen, 1975). Recently
a chronic human myelogenous leukaemic
cell line has been studied in nunu mice
(Lozzio, Lozzio and Machado, 1976),
butthe growth ofacute myeloid leukaemia
(AML)hashithertonotbeenachieved. We
now report the growth of AML as discrete
subcutaneous tumours in T- B+ mice.
Mice.-As in the previous studies of
Franks et al., 1973, 1975a, b, 1976a;
Franks, Bishop and Reeson, 1976b), female
CBA mice have been used from the
specific-pathogen-free unit at the National
Institute for Medical Research, and im-
mune deprivation has been achieved by
a method similar to that of Miller, Doak
and Cross (1963). In view of the fact
that T B+ mice are still capable of
mounting a weak cellular immune re-
sponse (Franks et al., 1976b), they were
treated s.c. with 0-25 ml ofantithymocyte
serum (ATS) prior to inoculation with
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leukaemic cells, and at intervals during
the following 3 weeks. ATS was pre-
pared by the method of Levey and
Medawar (1966).
Cells.-To date, fresh cells from 7
untreated patients and frozen cells from 4
untreated patients have been implanted
into 40 and 31 mice respectively. In
addition, 7 mice received normal bone
marrow cells. Each mouse wasinoculated
s.c. with about 5 x 108 cells in a 02-ml
inoculum into one site over the abdomen.
The leukaemic cells were obtained from
fresh blood by sedimentation with 1%
methyl cellulose. The buffy layer was
removed after 15 min, and washed once
in medium RPMI 1640. Frozen cells,
previously stored in liquid N2, were
thawed at 37°C, and then diluted by
adding RPMI 1640 as single drops over
10 min, to ensure good viability (Balkwill,
Pindar and Crowther, 1974; Williams,
FicatandOliver, inprepn.). The cellswere
washed once.
All 7 patients studied had confirmed
AML, as defined by standard criteria
(Crowther et al., 1973). The range of
total white cell counts was 15-4 x 103
to 161 0 x 103 white cells/mm3, and the
blast cell content varied between 30%
and 92%.
Tumour growth.-Growth of the im-
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planted cells was assessed by measuring
the vertical and transverse diameters of
the developing tumours, using vernier
calipers. Twenty-two days after implan-
tation, or sooner if there was evidence
of regression, the mice were killed, and
the tumours submitted for histology and
electron microscopy. The human cellular
content of the tumours was established
by Y-fluorescence ofthe interphase nuclei,
using the method of Polani and Mutton
(1971).
Results
Cells from 5/7 patients studied pro-
duced tumours in all the mice inoculated
(Fig. 1). Eight days after implantation,
21 (52.5%) of the mice inoculated with
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FIG. 1.- Surface area and survival of AML
tumours in T- B+ mice. Each symbol
type represents cells from one patient.
fresh cells had progressively growing
tumours. By Day 16, 17 (42.5%) mice
still had palpable tumours, but by Day 22
the number of mice with AML tumours
was reduced to 9 (22.5%). In the mice
inoculated with frozen cells, only one
(3.2%) mouse had a palpable tumour at
Day 16. This was one of a group of 4
(12.9%) mice producing tumours at 8
days, which had all been inoculated with
frozen cells from one patient. All the
mice inoculated with normal bone marrow
produced small subcutaneous nodules at
3 days, but by Day 7 the nodules had
disappeared. Fig. 2 shows the growth
curves for fresh AML cells and normal
bone marrow.
All the tumourigenic leucocytes, when
grown in vitro (Balkwill and Oliver,
1976), generated glass-adherent cells with
the characteristics of abnormal macro-
phages. AML cells from the 2 patients
whose blood did not induce tumours in
the mice, did not have this capacity for
in vitro differentiation into macrophages.
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FiG. 2.-Growth of fresh AML cells and normal
bone marrow in T- B+ mice.
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FIG. 3.-Electronmicrograph of the predominant cell type in an AML tumour. x 6000.
Although the surface areas of tumours
developing from cells of different patients
showed some variation, there was little
variation in growth, of tumours from
cells from the same patient.
Tumoursfrom 6patients wereexamined
histologically, and at least 2 tumour-
bearing mice per patient were studied.
The appearances were remarkably con-
sistent. All tumours had a centre of
necrotic cells with intact skin epithelium.
The tumour itself consisted of a solid
mass of cells of rather uniform type, with
large pale nuclei and abundant eosino-
philic cytoplasm (Fig. 3). The cells
grew in sheets and columns, and infiltrated
fat and striated muscle. Mitotic figures
were numerous, and eosinophilic nuclear
inclusions and binucleate cells were com-
mon. The appearances were those of
a reticulum-cell sarcoma or histiocytic
lymphoma. Fibroblasts and young ves-
sels were seen at the periphery of the
necrotic area, and were taken to indicate
a host reaction to the tumour. Variable
numbers of polymorphs were seen in
and around the tumour mass, but lympho-
cytes and plasma cells were scanty.
Histological examination of the small
short-lived nodules induced by normal
bone marrow showed scattered degenerate
cells and a non-specific inflammatory
reaction only.
Electronmicroscopy of 2 tumours re-
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vealed that the predominant cell had
the ultrastructural features of the neo-
plastic reticulum cell (Carr, 1975) (Fig. 4).
Other cells present included macrophages,
some with atypical nuclear and cyto-
plasmic features, and granulocytes.
This study shows that AML can be
grown as discrete tumours, after s.c.
implantation in T- BA+ mice. Fresh
cells have a greater capacity for survival
and growth than cells which have been
frozen. Normal bone marrow cells do
not survive beyond a few days. The
latter is consistent with previous studies
on non-oncogenic cell lines in T- BA+
mice (Stanbridge et al., 1975).
Fluorescence of the Y chromosome
in interphase nuclei confirmed that leuk-
aemic cells retain their human karyotype
after 22 days in the mouse. Further-
more, the developing tumours examined
were found to be composed of human,
not mouse, cells.
It is not clear why the majority of
AML tumours start regressing 6 days
after inoculation, unlike many solidhuman
tumours and oncogenic cell lines, which
continue to grow for several months
(Franks et al., 1973, 1975a, b, 1976a, b;
Cobb and Mitchley, 1974; Stanbridge et
al., 1975). This may be related to the
preferential formation of neoplastic reti-
culum cells, which appear to be the
predominant cell type in the tumours,
and which may have limited potential
for sustained division. This observation
is being studied further.
We would like to thank Mr D. E.
Mutton of the Department of Paediatric
Research, Guy's Hospital, London SEI
9RT, for carrying out the Y-fluorescence
studies.
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